How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
AI In Vitro Diagnostic Market
- By Technology: Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Expert Systems
- By Application: Disease Diagnosis, Biomarker Discovery, Drug Development, Genetic Testing, Pathology Analysis
- By End User: Hospitals and Clinics, Diagnostic Laboratories, Pharmaceutical Companies, Research Institutes, Biotechnology Companies
- By Product Type: Software Platforms, Imaging Analysis Tools, Predictive Analytics Solutions, Data Management Systems, Decision Support Systems
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Machine Learning leads By Technology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the AI In Vitro Diagnostic Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Technology 5
Application 5
End User 5
Product Type 5
Companies profiled
Siemens Healthineers
Abbott Laboratories
Roche Diagnostics
Thermo Fisher Scientific
GE Healthcare
Philips Healthcare
IBM Watson Health
Hologic Inc.
BioMérieux
Q2 Solutions
Guardant Health
PathAI
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GE Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Philips Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →IBM Watson Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Hologic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →BioMérieux
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Q2 Solutions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Guardant Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →PathAI
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Freenome
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Grail Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sophia Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,829M by 2033 · 7.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Machine Learning54.0
- Deep Learning11.1
- Natural Language Processing12.6
- Computer Vision12.7
- Expert Systems9.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,446M → $2,431M · 6.7%
Europe$1,008M → $1,749M · 7.1%
Asia Pacific$920.1M → $1,562M · 6.8%
Latin America$569.6M → $982.4M · 7.1%
Middle East and Africa$438.1M → $757.4M · 7.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.472026
7.482027
7.502028
7.522029
7.522030
7.552031
7.552032
7.562033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Siemens Healthineers14.7
- Abbott Laboratories19.9
- Roche Diagnostics9.7
- Thermo Fisher Scientific9.2
- GE Healthcare12.0
- Philips Healthcare6.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Technology29.7%
Application28.5%
End User19.4%
Product Type22.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.5
- Europe23.4
- Asia Pacific20.9
- Latin America13.1
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Siemens Healthineers | 74 | 78 | 81 | 77 | 85 | 86 | 80 |
| Abbott Laboratories | 91 | 72 | 68 | 74 | 81 | 74 | 77 |
| Roche Diagnostics | 68 | 82 | 86 | 67 | 88 | 87 | 80 |
| Thermo Fisher Scientific | 64 | 68 | 70 | 81 | 80 | 79 | 74 |
| GE Healthcare | 53 | 64 | 76 | 57 | 70 | 54 | 62 |
| Philips Healthcare | 65 | 63 | 65 | 53 | 67 | 71 | 64 |
| IBM Watson Health | 45 | 58 | 62 | 54 | 61 | 55 | 56 |
| Hologic Inc. | 46 | 39 | 45 | 42 | 58 | 46 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Siemens Healthineers
- Abbott Laboratories
- Roche Diagnostics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Siemens Healthineers | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Abbott Laboratories | ✓ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Roche Diagnostics | ✓ | ◐ | ✓ | − | ✓ | ◐ |
| Thermo Fisher Scientific | ◐ | ✓ | − | ✓ | ✓ | ◐ |
| GE Healthcare | ◐ | − | ✓ | ◐ | ◐ | ◐ |
| Philips Healthcare | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| IBM Watson Health | − | − | ◐ | ◐ | − | − |
| Hologic Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Siemens Healthineers80
2Roche Diagnostics80
3Abbott Laboratories77
4Thermo Fisher Scientific74
5Philips Healthcare64
6GE Healthcare62
7IBM Watson Health56
8Hologic Inc.46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Siemens HealthineersRoche Diagnostics
Challenger2
Strong scale, closing on the leaders.
Abbott LaboratoriesThermo Fisher Scientific
Contender2
Focused players with pockets of strength.
GE HealthcarePhilips Healthcare
Niche2
Specialists in a single segment or region.
IBM Watson HealthHologic Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technology in North America, then scale across AI In Vitro Diagnostic Market — a $532M beachhead inside a $10.3B market.
Beachhead (SOM)$532Mobtainable near-term
Serviceable (SAM)$3.68Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Machine Learning
Best fit — highest urgency & budget in Technology.
Economic buyer81 fit
Deep Learning
Strong fit — clear ROI and a fast path to value.
End user68 fit
Natural Language Processing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel30%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Technology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win AI In Vitro Diagnostic Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified22%
Evaluation13%
Closed-won7%
$10.9KCAC
$49KLTV
4.5:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
AI In Vitro Diagnostic Market is a durable-growth opportunity — $9.65B by 2033, compounding at 7.2%.
TAM · 2025$5.54Btoday
TAM · 2033$9.65Bforecast
CAGR7.2%2027–2033
Cumulative$66.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.65BTotal addressable market
SAM$3.47BServiceable available market
SOM$626MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.2% CAGR
Demand compounds through 2033, outpacing GDP across Technology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.65BLarge & growingTAM by 2033 at 7.2% CAGR
$3.47BServiceable nowreachable with today’s model
$626MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.53BBear4.7% CAGR
$9.65BBase7.2% CAGR
$12.4BBull9.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
AI In Vitro Diagnostic Market — a $10.9B market by 2033. Plan: grow share from 8.2% to 15.9%.
Market size · 2033$10.9Btotal addressable
Market CAGR9.1%2027–2033
Target share15.9%from 8.2% today
Revenue ambition$1.73Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.2% | 15.9% | At risk |
| Revenue | $823M | $1.73B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.4% | 45.3% | At risk |
| Customer retention | 85.5% | 92.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $207M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Technology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the AI In Vitro Diagnostic Market conversation — a $10.1B market you can size, segment and defend in minutes.
Market size · 2033$10.1Btotal opportunity
Growth11.6%CAGR to 2033
Addressable buyers1,761+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology
Goal Grow share in Technology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 3 mopayback period
$64K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Siemens HealthineersAbbott LaboratoriesRoche DiagnosticsThermo Fisher ScientificGE HealthcarePhilips HealthcareIBM Watson HealthHologic Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your AI In Vitro Diagnostic Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
AI In Vitro Diagnostic Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Medical Tourniquets Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportTumor Necrosis Factor Receptor Superfamily Member 4 Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportMedical Sevoflurane Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportDisposable Medical Protective Masks Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportAtypical Chemokine Receptor 3 Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportMetabotropic Glutamate Receptor 1 Market
Market size, share, segmentation and regional forecast.
$466M market · 2025 base year
View report5 Hydroxytryptamine Receptor 2B Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportSecondary Antibodies Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportHuman Somatotropin Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportAI In Remote Patient Monitoring Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportInhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAI in Radiology Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.